• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Improvement of MICROBIOME HEALTH INDEX™ in Patients with Recurrent Clostridioides difficile Infections Following RBX2660 Treatment is Associated with a Reduction in Antimicrobial Resistance Genes

Courtney Jones BS, Ken Blount PhD, Tonya Ward PhD, Elena Deych MS, Bill Shannon PhD, MBA

Download this poster (401 KB)

ASM Microbe 2019
June 20-24, 2019, San Francisco, CA

Background

  • RBX2660, a standardized, stabilized microbiota restoration drug has been shown to prevent recurrent Clostridiodies difficile infections (rCDI).
  • A preliminary analysis demonstrated decolonization of multidrug-resistant organisms (MDRO) in association with clinical response.
  • In parallel, we are developing a MICROBIOME HEALTH INDEX™ (MHI™) to monitor dysbiosis and microbiome restoration.
  • Given the public health challenges related with MDROs, we evaluated MHI as a potential sentinel of MDRO colonization among rCDI patients who responded to RBX2660 in a Phase 2 clinical trial.

Methods

  • The PUNCH CD2 Phase 2 trial (NCT02299570) compared RBX2660, a microbiota-based investigational drug for treatment of rCDI, to placebo.
  • 127 participants were enrolled, randomized, and treated in three cohorts: Group A: two doses of RBX2660; Group B, two placebo doses; Group C, one dose of RBX2660 and one dose of placebo.
  • Samples were collected prior to treatment (BL) and 7, 30 & 60 days after treatment.
  • This analysis is based on samples from 55 patients who responded to RBX2660 treatment in Groups A and B (pooled) and dosed RBX2660 product samples.
  • Stool samples were sequenced using BoosterShot (CoreBiome, Minneapolis, MN), an ultra-shallow shotgun sequencing method.
  • MICROBIOME HEALTH INDEX™ (MHI™) values were calculated based on relative abundances at the class level for selected classes.
  • Prior receiver operator characteristic analyses defined an MHI cut-point of 8.2 for distinguishing rCDI subjects prior to treatment from the representative microbiome composition of RBX2660.
  • Relative abundance of antimicrobial resistance (AMR) genes and enzymes were determined for all samples based on a threshold of ≥ 90% coverage when compared to the MEGARes database .

RBX2660 Efficacy in a Phase 2 Controlled Trial

  • See poster (401 KB)

Microbiome Composition Shifts Post-RBX2660

  • See poster (401 KB)

MICROBIOME HEALTH INDEX™ (MHI™) Analysis

  • See poster (401 KB)

Relationship Between MHI and Antimicrobial Resistance Genes

  • See poster (401 KB)

Conclusions

  • MHI can effectively distinguish patients with dysbiosis from healthier patients, as defined by the RBX2660 product profile and the Human Microbiome Project.
  • MHI inversely correlates with AMR gene abundance in a cohort of rCDI patients who had successful response to RBX2660.
  • These results suggest MHI as a potential sentinel of MDRO colonization, and this role will be evaluated in future cohorts outside of the rCDI patient population.

Microbiota Restoration Therapy Posters Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT